Skip to main content
padlock icon - secure page this page is secure

Nα-Methylhistamine Safety and Efficacy in Migraine Prophylaxis: Phase I and Phase II Studies

Buy Article:

$52.00 + tax (Refund Policy)

Objective.—To study the therapeutic potential of the subcutaneous administration of N α-methylhistamine in migraine prophylaxis.

Background.—The histamine catabolite, N α-methylhistamine, possesses a selective affinity for H3 receptors. We consequently considered it viable to conduct a clinical pharmacological study to evaluate the safety and efficacy of this histaminergic H3 agonist in migraine prophylactic treatment, which specifically may inhibit the neurogenic edema response involved in migraine pathophysiology.

Methods.—Phase I.—In a clinical trial of 30 healthy volunteers, the effects of the subcutaneous administration of N α-methylhistamine and placebo were studied to assess undesirable symptomatic effects.

Phase II.—In a clinical open study, we evaluated the efficacy of N α-methylhistamine in reducing headache intensity, frequency, and duration; and in decreasing analgesic intake in 18 patients with migraine.

Results.—Phase I.—None of the variables studied showed significant differences (P>.05), and no secondary effects were observed at doses below 10 ng.

Phase II.—N α-methylhistamine, at doses of 1 to 3 ng, significantly reduced (P<.0001) the frequency, intensity, and duration of migraine attacks, as well as the need for rescue analgesics. However, at doses greater than 3 ng, patients experienced intense headache.

Conclusions.—The present study provides evidence of the safety and efficacy of N α-methylhistamine applied subcutaneously at doses of 1 to 3 ng twice a week.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: H3 receptors; N α-methylhistamine; migraine prophylaxis; pathophysiology; safety and efficacy

Document Type: Research Article

Affiliations: 1: Department of Neurology, Unidad de Investigación Médica en Epidemiología Clínica, Hospital General de Zona UMF No 1 IMSS 2: Unidad de Investigación en Servicios de Salud, Cuauhtémoc IMSS 3: Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Mexico.

Publication date: April 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more